CLINICAL_TRIALS
trial_result
· 2016-10-07
Clinical Trial Update: Fasiglifam 25 mg BID vs 50 mg QD [Phase 2]
Summary
Phase 2 trial evaluating Fasiglifam (TAK-875) at 25 mg twice daily versus 50 mg once daily for type 2 diabetes was terminated, with results posted in 2016.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Takeda | Conditions: Type 2 Diabetes Mellitus | Phase 2 | Status: TERMINATED | Results posted: 2016-10-07